MedTrace Logo

Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists

NCT02622555 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 221

Last updated 2015-12-04

No results posted yet for this study

Summary

Overactive bladder syndrome complicates life for many women. 60-70% of women report improvement with treatment but the antikolinergic treatment is often limited by the adverse events, for example dry mouth, obstipation and urinary retention. Mirabegron is a b3-adrenoreceptor agonist which induces detrusor relaxation. Earlier studies has demonstrated similar efficacy comparing Mirabegron with antimuscarinics but a significant reduction of adverse events. The aim of the present study is to survey cardiovascular adverse events with Mirabegron treatment in a general population suffering from overactive bladder syndrome.

Conditions

Interventions

DRUG

Mirabegron

Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine

Sponsors & Collaborators

Principal Investigators

  • Daniel Altman, Ass. prof. · Karolinska Institutet

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02622555 on ClinicalTrials.gov